<DOC>
	<DOCNO>NCT00446511</DOCNO>
	<brief_summary>The purpose extension study compare long-term safety valsartan versus enalapril , effectiveness combination valsartan enalapril versus enalapril alone child hypertension .</brief_summary>
	<brief_title>Extension Study Assess Long Term Safety , Tolerability , Efficacy Valsartan Enalapril Combined Alone Children With Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Enalapril</mesh_term>
	<mesh_term>Enalaprilat</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<criteria>Successful completion 12 week doubleblind treatment core protocol CVAL489K2302 . Patients participate study CVAL489K2302 may discontinue prematurely due uncontrolled hypertension define MSSBP &gt; 20 % , &lt; 25 % 95th percentile age , gender , height visit 5 , qualifies patient entry extension study . Renal artery stenosis . Current diagnosis heart failure ( NYHA Class IIIV ) . Second third degree heart block without pacemaker . Concurrent potentially life threaten arrhythmia symptomatic arrhythmia . Clinically significant valvular heart disease . Patient demonstrate clinically significant ECG abnormality associate leave ventricular hypertrophy AV block control pacemaker . Previous solid organ transplantation except renal , liver heart transplantation . Renal , liver heart transplant must occur least 6 month prior enrollment . Patient must stable dos immunosuppressive therapy 3 month deem clinically stable investigator . Patients experienced adverse event consider serious drug relate protocol CVAL489K2302 . Other protocoldefined inclusion/exclusion criterion apply study .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>child</keyword>
	<keyword>pediatrics</keyword>
	<keyword>high blood pressure</keyword>
	<keyword>hypertension</keyword>
	<keyword>valsartan</keyword>
	<keyword>enalapril</keyword>
</DOC>